SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）

NCT06767007 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Locally Recurrent Rectal Cancer

Interventions

RADIATION: Stereotactic Body Radiation Therapy (SBRT)
DRUG: PD1
DRUG: Chemotherapy

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]